Bioventus (BVS) vs iRadimed (IRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Bioventus (BVS) has outperformed iRadimed (IRMD) over the past year, gaining 92.0% versus a gain of 14.9%. Over five years, IRMD leads with a +133.1% price change compared with -6.4% for BVS. iRadimed is the larger company by market cap ($1.09 billion vs $872.3 million), about 1.3 times the size.
On valuation, Bioventus trades at a lower forward P/E (13.9x vs 34.8x for iRadimed). iRadimed pays a dividend yielding 0.90%, while Bioventus does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | IRMD |
|---|---|---|
| Share price | $12.77 | $85.47 |
| Market cap | $872.26M | $1.09B |
| 1-day change | -2.52% | +0.77% |
| YTD return | +71.64% | -12.14% |
| 1-year return | +92.03% | +14.93% |
| 5-year return | -6.38% | +133.08% |
| P/E ratio (TTM) | 16.80 | 47.75 |
| Forward P/E | 13.88 | 34.84 |
| EPS (TTM) | $0.76 | $1.79 |
| Dividend yield | 0.00% | 0.90% |
| Annual dividend | $0.00 | $0.77 |
| 52-week high | $15.89 | $107.90 |
| 52-week low | $6.37 | $71.34 |
| Distance from 52-week high | -19.65% | -20.79% |
| Average volume | 627.38K | 127.24K |
| Shares outstanding | 68.31M | 12.79M |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed IRMD by 77.1 percentage points over the past year.
- iRadimed trades at a higher earnings multiple (47.7x vs 16.8x trailing P/E).
BVS vs IRMD FAQ
Which is bigger, Bioventus or iRadimed?
iRadimed (IRMD) is larger, with a market capitalization of $1.09B compared with $872.26M for Bioventus (BVS).
Which stock has performed better over the past year, BVS or IRMD?
BVS returned +92.03% over the past 12 months, compared with +14.93% for IRMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BVS or IRMD?
BVS has the lower trailing P/E at 16.8, versus 47.7 for IRMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bioventus or iRadimed?
iRadimed pays a dividend yielding 0.90%, while Bioventus does not currently pay a regular dividend.
Are Bioventus and iRadimed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.